Health Headlines: Global Pharmaceutical Moves and Policy Changes

The health sector is facing significant changes, with the FDA restricting language, New York suing e-cigarette makers, AstraZeneca expanding in China, Eli Lilly stockpiling weight-loss drugs, Teva and Alvotech launching a Stelara biosimilar, Indian insurers hiking health premiums, and DOJ probing UnitedHealth's billing.

The U.S. Food and Drug Administration (FDA) is under scrutiny as scientists reveal they've been advised to avoid using terms like "woman," "disabled," and "elderly" in communications. This policy, reportedly misinterpreted from a presidential order, raises concerns within the department.

New York's Attorney General Letitia James is taking on major e-cigarette manufacturers, accusing them of marketing products to teens with alluring flavors reminiscent of candy and cereals. The lawsuit seeks substantial damages for what is described as a negligence leading to a youth vaping epidemic.

On the business front, AstraZeneca is bolstering its Chinese market presence through a $160 million deal with FibroGen for their anemia drug. Meanwhile, Eli Lilly is gearing up for the release of its weight-loss pill by securing a hefty pre-launch inventory, despite lacking complete trial data.